Palbonix 125 mg Capsules (Palbociclib) are a targeted oral oncology medicine used in the treatment of hormone receptor‑positive (HR+), HER2‑negative advanced or metastatic breast cancer. Palbociclib works by inhibiting enzymes (CDK4/6) that help cancer cells divide, thereby slowing tumor progression. Palbonix is typically used in combination with hormone therapies such as letrozole or fulvestrant and is taken in 28‑day cycles (21 days on treatment, 7 days off). Regular blood monitoring for low white blood cell counts and liver function tests is an important part of therapy. Available in Pakistan through licensed oncology pharmacies; a valid doctor’s prescription is required to purchase and use this medicine safely.